A 60-Year-Old Woman in Chronic Phase Chronic Myeloid Leukemia (CML) Who Started Therapy With Imatinib Mesylate CME

Prof. John M. Goldman, DM, FRCP FMed Sci Author Information and Disclosures

Release Date: May 20, 2008; Valid for credit through May 20, 2009

Credits Available
Physicians - maximum of 0.75 AMA PRA Category 1 Credit(s)™ for physicians

This CME program was created for use on eMedicine.com.

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the educational content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Legal Disclaimer

The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Copyright © 2008 education | outcomes | science
Novartis
Learning Objectives
Upon completion of this activity, participants should be better able to:
  • Discuss the results of clinical trials evaluating pharmacologic treatments for CML;
  • Evaluate the role of molecular testing and mutation analysis and of differentiating suboptimal responses and resistance;
  • Evaluate how dose optimization and novel agents can be integrated into the treatment algorithms for patients with CML;
  • Recognize the importance of monitoring patients with CML.
Author Disclosures
Prof. John M. Goldman, DM, FRCP FMed Sci
Disclosure: Sources of funding for research: Bristol-Myers Squibb, Novartis. Speakers' bureau/honorarium agreements: Bristol-Myers Squibb, Novartis.
 
education | outcomes | science
education | outcomes | science is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

education | outcomes | science designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. The American Medical Association has determined that non-US licensed physicians who participate in this CME activity are eligible for AMA PRA Category 1 Credit™.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.